-
Sulfo-Cy3 azide for Aqueous Bioconjugation
2026-09-19
Sulfo-Cy3 azide combines water compatibility with bright Cy3-range fluorescence for labeling alkyne-bearing oligonucleotides, proteins, and biological samples. Its strongest use-case is aqueous Click Chemistry fluorescent labeling when solvent burden, dye aggregation, and imaging stability can compromise developmental or cellular assays.
-
High Yield T7 Biotin16 RNA Labeling Kit
2026-09-18
The High Yield T7 Biotin16 RNA Labeling Kit, SKU K1082, is an in vitro RNA-labeling tool built around T7 transcription and biotin-tagged nucleotide incorporation. It can support affinity-based RNA workflows, but it does not directly measure m6A or reproduce the arginine methylation-dependent METTL14–SMN biology described in the reference study.
-
EZ Cap™ Firefly Luciferase mRNA: Workflow
2026-09-17
Build a more interpretable reporter experiment with capped, m1Ψ-modified Firefly Luciferase mRNA for separating delivery, translation, and cell-health effects. This practical workflow combines signal kinetics, controls, and absolute RNA-quality thinking for reliable assay development.
-
BMAL1 Phase Separation and Circadian Transcription
2026-09-17
Gao et al. show that BMAL1 forms dynamic nuclear condensates that function as transcriptional hubs for circadian gene regulation. Their experiments connect an N-terminal intrinsically disordered region and phosphorylation-sensitive phase separation with the recruitment of CLOCK, p300, and MED1, as well as rhythmic transcription and locomotor behavior.
-
Rottlerin PKC Inhibitor: Workflow Guide
2026-09-17
Build more interpretable PKC experiments with Rottlerin by combining concentration-response studies, orthogonal apoptosis readouts, and time-of-addition designs. This guide also translates evidence from a grass carp reovirus entry study into practical controls for distinguishing signaling effects from nonspecific cytotoxicity.
-
Stable Yeast Expression of Exendin-4 for Type 2 Diabetes
2026-09-16
Balius et al. developed recombinant Exendin-4 production models in Escherichia coli and Saccharomyces cerevisiae, with chromosomal integration in yeast producing an immunoassay-detectable protein at the expected size. The study establishes a useful synthetic-biology foundation for locally propagated production, while also showing that functional validation, purification, formulation, and clinical translation remain necessary.
-
Cabazitaxel (XRP6258) Workflow Guide
2026-09-15
Cabazitaxel (XRP6258) is a solvent-compatible research compound for examining microtubule dynamics disruption in taxane-resistant and P-glycoprotein-expressing cancer models. It should be prepared in DMSO or ethanol rather than water, used promptly after solution preparation, and interpreted as an exploratory antiproliferative treatment rather than a validated clinical or dose-equivalence protocol.
-
Perphenazine: From D2 Antagonism to Host Defense
2026-09-15
Perphenazine is best known as a dopamine D2 receptor antagonist, but its broader phenothiazine pharmacology creates a compelling platform for translational research spanning neurobiology, mitochondrial stress, opioid tolerance, and host-directed antibacterial defense. This article outlines how to convert that mechanistic breadth into disciplined experimental strategy without overstating clinical maturity.
-
Remimazolam, Hippocampal HIF-1α, and POCD
2026-09-14
A 2026 study in aged mice links remimazolam-mediated protection from postoperative cognitive dysfunction to reduced hippocampal HIF-1α expression and neural cell apoptosis. Pharmacological inhibition with YC-1 produced a similar phenotype without an apparent additive effect, supporting HIF-1α as a mechanistic pathway while leaving important questions about compound specificity and translational relevance.
-
PF-562271 HCl in CAML-Focused Cancer Research
2026-09-14
PF-562271 HCl offers a selective way to interrogate FAK/Pyk2 signaling in cancer research. This article connects its reversible kinase pharmacology with emerging assays for circulating phagocytic polyploid giant cancer macrophages while distinguishing established evidence from testable hypotheses.
-
Rotigotine Hydrochloride in PD Research
2026-09-13
Rotigotine hydrochloride is a versatile dopamine D2/D3 receptor agonist for connecting cellular neuroprotection, dopaminergic signaling research, and rodent Parkinson’s disease models. This workflow-centered guide shows how to select concentrations, compare administration routes, interpret bladder-function data, and troubleshoot reproducibility limits.
-
DNP-Induced seRNA Drives NPC Metastasis
2026-09-12
The 2023 study identifies a carcinogen-responsive super-enhancer RNA, seRNA-NPCm, that promotes nasopharyngeal carcinoma metastasis through an NPM1/c-Myc/NDRG1 regulatory axis. By combining RNA-seq, GRO-seq, ChIP-seq, functional perturbation, animal models, and patient tissue analysis, the work connects chemical exposure to enhancer-mediated transcriptional control and metastatic behavior.
-
Cyanin Chloride in a Human Psoriasis Model
2026-09-12
A 2024 study evaluated cyanin chloride across chemical antioxidant assays, macrophage inflammation, and cytokine-stimulated HaCaT keratinocytes. Its main contribution was to connect reduced inflammatory signaling, STAT3 modulation, transepithelial electrical resistance, and filaggrin expression in one in vitro psoriasis-relevant workflow, while leaving clinical translation and aglycone–glycoside equivalence unresolved.
-
Mitomycin C Workflows for Cancer Research
2026-09-11
Build more interpretable DNA-damage and apoptosis assays with Mitomycin C, from solvent handling through TRAIL-sensitization studies. This practical guide also shows how target-specific controls from antiviral genome-editing research can strengthen cancer assay design without overstating cross-domain evidence.
-
Perphenazine: D2 Antagonist Research Guide
2026-09-11
Perphenazine is a dopamine D2 receptor antagonist with additional histamine, muscarinic, and adrenergic receptor activity. Research benchmarks include mitochondria-mediated cell death induction in SH-SY5Y cells, opioid tolerance suppression in rats, and phenothiazine-associated macrophage ROS and autophagy responses.